Physician profile
Philip A Dy
NPI 1710076567
$6,809.88
in general payments reported to CMS, 2019-2025
54 companies · $1,160 in 2025
The $1,160 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $103 · 2021: $892 · 2022: $1,608 · 2023: $1,088 · 2024: $1,091 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,277 · Education: $61.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,277.37 |
| Education | $61.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $827.03 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $425.02 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $373.28 | 2019-2025 | |
| Janssen Biotech, INC. | $370.15 | 2019-2025 | Rybrevant |
| Pharmacyclics LLC, An Abbvie Company | $308.83 | 2019-2023 | Imbruvica, Epkinly |
| Celgene Corporation | $290.89 | 2019-2025 | Reblozyl, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $280.03 | 2021-2024 | Enhertu, Lynparza, Calquence |
| Astellas Pharma US INC | $270.26 | 2019-2025 | Xtandi, Padcev, Xospata |
| Merck Sharp & Dohme LLC | $256.03 | 2021-2025 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $204.80 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Rigel Pharmaceuticals, INC. | $189.68 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Genzyme Corporation | $187.40 | 2019-2024 | |
| Genentech USA, INC. | $183.53 | 2019-2023 | Venclexta, Herceptin, Kadcyla |
| Daiichi Sankyo INC. | $165.36 | 2021-2025 | Injectafer, Enhertu |
| Emd Serono, INC. | $164.97 | 2019-2025 | Bavencio |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Dy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.